VEN (Venetoclax)

DRUG3 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Yehui Tan, The First Affiliated Hospital of Soochow University

Conditions

Adult T-cell Leukemia/LymphomaLymphomaMantle Cell LymphomaMyelodysplastic NeoplasmsTransplantation

Early Phase 1

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

CompletedNCT03295240

Memorial Sloan Kettering Cancer CenterLymphoma, Mantle Cell Lymphoma

Start: 2017-09-20End: 2024-01-22Updated: 2025-05-13

Phase 2

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

RecruitingNCT07047183

Yehui TanMyelodysplastic Neoplasms, Transplantation

Start: 2025-07-01End: 2029-06-30Target: 46Updated: 2025-08-08

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

RecruitingNCT07159620

The First Affiliated Hospital of Soochow UniversityAdult T-cell Leukemia/Lymphoma

Start: 2025-09-01End: 2030-09-01Target: 27Updated: 2025-09-08

Related Papers

PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VENETOCLAX IN RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA

Hematological Oncology2021-06-012 citations